ESMO

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.

Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

Dato-DXd lengthened the average time it took patients with HR-positive, HER2-low or -negative metastatic breast cancer to experience disease progression, study results showed.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer.

For the first time, a drug combination (Padcev plus Keytruda) outperformed frontline chemotherapy for patients with locally advanced or metastatic urothelial carcinoma.

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.

Treatment with Retevmo, compared with Cabometyx or Caprelsa, improved progression-free survival and overall response rate in patients with advanced RET-mutant medullary thyroid cancer who were multikinase inhibitor-naïve.

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.

Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.

Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.